Related Experiment Videos
[Angiotensin-converting enzyme inhibitors and anesthesia]
J K Larsen1, M B Nielsen, T W Jespersen
1Arhus Amtssygehus, anaestesiologisk afdeling.
Ugeskrift for Laeger
|October 21, 1996
Summary
Angiotensin-converting enzyme (ACE) inhibitors may increase risks during anesthesia. Careful management is needed to mitigate potential adverse events like severe hypotension and pulmonary edema in patients on these medications.
Area of Science:
- Anesthesiology
- Cardiology
- Pharmacology
Background:
- Angiotensin-converting enzyme (ACE) inhibitors are widely used for hypertension and heart failure.
- Their use may complicate anesthetic management, potentially leading to adverse events.
Observation:
- Four cases are presented where patients on ACE inhibitors experienced anesthetic complications.
- These included severe hypotension with combined general and epidural anesthesia, fatal hypotension with spinal anesthesia, and fatal pulmonary edema after general anesthesia.
Findings:
- ACE inhibitor use is associated with an increased incidence of adverse anesthetic occurrences.
- Hypotension is a significant risk, particularly when combined with regional anesthesia or following surgery.
- Pulmonary edema may also occur, potentially linked to the timing of ACE inhibitor resumption.
Implications:
- The management of ACE inhibitors around surgery remains controversial.
- While discontinuing ACE inhibitors may increase risks, continuing them carries a known risk of hypotension.
- Proactive fluid management is crucial for patients on ACE inhibitors undergoing anesthesia to predict and counteract hypotensive episodes.